News & Events about Nkarta Inc.
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences: 22nd Annual Needham Virtual ...
Globe Newswire
3 months ago
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences: SVB Securities Global Biopharma ...
Ticker Report
5 months ago
Nkarta, Inc. (NASDAQ:NKTX Get Rating) has been given a consensus rating of Moderate Buy by the ten analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on ...
Globe Newswire
6 months ago
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors Induces Billion-Fold Expansion, Enabling Commercial-Scale Production of NK Cell Therapy ...
Ticker Report
8 months ago
Nkarta, Inc. (NASDAQ:NKTX Get Rating) CEO Paul J. Hastings sold 6,126 shares of the firms stock in a transaction that occurred on Wednesday, September 21st. The stock was sold at an average price of $13.01, for a total transaction of $79,699.26. Following the completion of the ...